SLAMF3 is expressed at much higher levels on MM cells and progenitor cells (i.e., cancer stem cells) than on normal immune cells and HSCs/HPCs, and a preclinical study demonstrated the potential therapeutic efficacy of SLAMF3 CAR-T therapy. The gene discussed is LY9; the disease is Miyoshi myopathy.